Top Markets
#1 Siacoin Siacoin +38.17%
#2 Official Trump Official Trump +31.38%
#3 Unit Pump Unit Pump +19.19%
#4 Pump.fun Pump.fun +19.19%
#5 EXOD EXOD +18.93%
#6 MowCat MowCat +18.76%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +18.50%
#8 Melania Meme Melania Meme +18.46%
#9 Mubarak Mubarak +17.60%
#10 The Bitcoin Bull The Bitcoin Bull +14.75%
Coin of the day
Siacoin Siacoin
Settings
Language
ENGLISH
Currency
USD
Theme
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
Rank in Stocks #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Share Price
$1.81
Last synced: 2026-08-21
Market Cap
$77.00M
Change (1 day)
1.30%
Change (1 year)
-23.63%
Country
US
Trade Annovis Bio, Inc. (ANVS)

Category

Healthcare
Revenue for Annovis Bio, Inc. (ANVS)
Revenue in Aug 2026 TTM: 0
According to Annovis Bio, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Annovis Bio, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH